Next Article in Journal
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
Next Article in Special Issue
DNA Damage Repair Defects and Targeted Radionuclide Therapies for Prostate Cancer: Does Mutation Really Matter? A Systematic Review
Previous Article in Journal
Functional Insights into Protein Kinase A (PKA) Signaling from C. elegans
Previous Article in Special Issue
Alpinumisoflavone Exhibits the Therapeutic Effect on Prostate Cancer Cells by Repressing AR and Co-Targeting FASN- and HMGCR-Mediated Lipid and Cholesterol Biosynthesis
 
 
Article

Article Versions Notes

Life 2022, 12(11), 1879; https://doi.org/10.3390/life12111879
Action Date Notes Link
article xml file uploaded 14 November 2022 11:15 CET Original file -
article xml uploaded. 14 November 2022 11:15 CET Update https://www.mdpi.com/2075-1729/12/11/1879/xml
article pdf uploaded. 14 November 2022 11:15 CET Version of Record https://www.mdpi.com/2075-1729/12/11/1879/pdf
article supplementary file uploaded. 14 November 2022 11:15 CET - https://www.mdpi.com/2075-1729/12/11/1879#supplementary
article html file updated 14 November 2022 11:17 CET Original file -
article html file updated 28 February 2023 22:55 CET Update -
article html file updated 2 March 2023 23:12 CET Update https://www.mdpi.com/2075-1729/12/11/1879/html
Back to TopTop